LNWTC
REGN icon

Laird Norton Wetherby Trust Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Sell
2,419
-216
-8% -$147K 0.03% 406
2026
Q1 		$2.04M Sell
2,635
-103
-4% -$78.9K 0.04% 311
2025
Q4 		$2.11M Buy
+2,738
New +$1.86M 0.04% 310

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Laird Norton Wetherby Trust Company's REGN Position: Q2 2026 in Review

Laird Norton Wetherby Trust Company reduced its Regeneron Pharmaceuticals (REGN) stake by 8.2% in Q2 2026, selling an estimated $147K and leaving 2,419 shares worth $1.51M. The position accounts for 0.03% of the portfolio, ranked #406.

Laird Norton Wetherby Trust Company first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.11M in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Laird Norton Wetherby Trust Company held 2,419 shares of Regeneron Pharmaceuticals worth $1.51M as of Q2 2026.
  • Laird Norton Wetherby Trust Company sold 216 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $147K.
  • Regeneron Pharmaceuticals made up 0.03% of Laird Norton Wetherby Trust Company's portfolio in Q2 2026, its #406 holding.
  • Laird Norton Wetherby Trust Company first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Laird Norton Wetherby Trust Company's Regeneron Pharmaceuticals position peaked at $2.11M in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q2 2026, filed 14 Aug 2026.